Immunome Stock - Sunday background on pipeline and positioning
Published on 06/21/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 14:37 UTC. Details in the imprint.
Immunome (US45254C1062) remains without a new market-moving announcement this weekend. Instead, the biotechnology company stands out through its evolving oncology and infectious-disease pipeline and the integration of Morphimmune after last year's all-stock combination according to the merger IR release dated 10/02/2023.
Background and data on Immunome stock
Investors can track Immunome's filings, merger documents and pipeline updates centrally to better understand the story behind the stock.
What recent filings show
Immunome last drew broader attention with its merger with Morphimmune, which closed in October 2023 and created a combined oncology-focused platform with cash runway into 2026 according to the companies' joint announcement.
The transaction was structured as an all-stock deal, with former Morphimmune shareholders owning a majority of the combined company upon closing, as outlined in the related SEC filings.
Background on pipeline and strategy
Since the merger, Immunome has focused on advancing a pipeline that includes antibody-drug conjugates and targeted radiotherapy candidates aimed at solid tumors and hematologic malignancies, according to company presentations.
The company also maintains earlier-stage infectious-disease programs informed by its antibody discovery platform, though oncology has become the primary strategic focus post-deal, consistent with management's stated priorities.
How the company makes money
Immunome currently generates negligible product revenue and is primarily funded through equity capital and potentially collaboration payments, as is typical for a clinical-stage biotech without approved therapies.
Where the stock trades today
The shares of Immunome trade on the Nasdaq; the latest verifiable quote shows the stock last changing hands at around the mid-single-digit dollar level during recent sessions, with exact real-time pricing subject to intraday market updates in USD.
Key facts on Immunome stock
- Company: Immunome Inc.
- ISIN: US45254C1062
- Ticker: IMNM
- Venue: Nasdaq
- Sector / Industry: Health Care / Biotechnology
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
